Published on 15 Nov 2023 on Insider Monkey via Yahoo Finance
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript November 14, 2023
Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today. [Operator Instructions] And I will now hand the call over to Louise Barrett, Senior Vice President, Legal Affairs, to begin. Please go ahead.
Louise Barrett: Thank you, Harry. Good morning, and welcome to Interim Therapeutics’ Third Quarter 2023 Financial Results and Business Update Conference Call. A press release with our third quarter results was issued earlier this morning and can be found on our website. We are joined this morning by Corey Fishman, CEO; and Judy Matthews, CFO. Cory will provide some opening remarks, Judy will provide details on our financial results, and then we’ll open the lines for Q&A. In addition, we’ll be extending the Q&A portion to answer a few questions we’ve been routinely receiving from some of our shareholders. Before we begin, I would like to remind you that some of the information presented on this conference call today will contain forward-looking statements concerning our plans, strategies and prospects for our business, including the development, therapeutic and market potential of oral sulopenem, the timing and results of top line data from REASSURE clinical trial, our ability to address the deficiency set out in the complete response letter received from the FDA in July 2021, the expected timing of resubmission of our NDA and timing of review of the NDA by the FDA; the term and coverage provided by our patents; the sufficiency of our cash resources; and evaluating of corporate strategic and financing strategies and alternatives to fund future development operations, including the issue of new shares for cash.